(Updated - September 26, 2017 9:52 AM EDT)

(updated to add comments)Chardan Capital Markets lowered its price target on ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Hot Comments

Axovant Sciences (AXON) PT Lowered to $9 at Evercore ISISeptember 26, 2017 12:07 PM Axovant Sciences (AXON) PT Lowered to $25 at Cowen; Lewy Body Program Remains FocusSeptember 26, 2017 11:48 AM UPDATE: Piper Jaffray Downgrades Axovant Sciences (AXON) to NeutralSeptember 26, 2017 10:53 AM Oppenheimer Downgrades Axovant Sciences (AXON) to PerformSeptember 26, 2017 10:48 AM Baird Downgrades Axovant Sciences (AXON) to Neutral, $6 PTSeptember 26, 2017 9:38 AM Axovant (AXON) Says its Intepirdine Phase 3 MINDSET Trial in AD Did Not Meet its co-Primary Efficacy EndpointsSeptember 26, 2017 7:02 AM Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's DiseaseSeptember 26, 2017 7:00 AM